16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to a...
23:30 , Sep 26, 2017 |  BC Extra  |  Company News

GSK, Gilead, Shire gain RDPAC membership

China’s R&D-based Pharmaceutical Association Committee (RDPAC) approved new member applications from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Gilead Sciences Inc. (NASDAQ:GILD) and Shire plc (LSE:SHP; NASDAQ:SHPG). In 2013, media outlets reported that GSK voluntarily withdrew its membership from...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking more...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Factor VIII drugs regulatory update

EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) began a review of approved Factor VIII drugs to treat hemophilia A to evaluate the risk of patients developing inhibitors when starting treatment. The review follows a published study...
07:00 , Apr 11, 2016 |  BC Week In Review  |  Clinical News

Adynovi regulatory update

Baxalta said Japan approved Adynovate to treat hemophilia A in patients ages >=12. Adynovate is a pegylated form of Baxalta’s Advate recombinant Factor VIII that uses PEGylation technology from Nektar and has a longer...
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

1Q approvals

1Q approvals CompanyApprovalAlexion Pharmaceuticals Inc. (NASDAQ:ALXN)Japan approves Kanuma sebelipase alfa to treat lysosomal acid lipase deficiency (LAL-D)Amgen Inc. (NASDAQ:AMGN)Japan approves Repatha evolocumab to treat familial hypercholesterolemia or hypercholesterolemia in patients at high risk of cardiovascular events...